
Fifth Artificial Pancreas Workshop
Registration
Event Details
Meeting Objectives
- Towards Fully Automated and Personalized Diabetes Management Systems. What is needed?
- Challenges and Opportunities for higher Accessibility, Adoption, and Improvement in Quality of Life of People with Diabetes
Purpose
The purpose of this workshop is to discuss in a multi-disciplinary forum, the current and potential future challenges for the development, testing, accessibility and adoption of fully automated diabetes management technologies and their components. Topics to be discussed include:
- Lessons learned from Clinical Trials. Clinical testing modalities for real world translatability.
- Discussion of current state of interoperability and perspectives for the future.
- Adaptation of systems throughout the life span and to special populations.
- Potential benefits of multihormone closed loop systems and the use of adjuvant therapies.
- Artificial intelligence/ ML and integration strategies for personalized systems.
- Technical challenges and potential solutions in glucose sensing and more physiological and durable insulin/pancreatic hormones delivery.
- Human psychosocial factors, quality of life, ethical considerations and health disparities in the adoption and access to these technologies.
- Prospective areas of research emphasis to accelerate the availability of wearable, affordable, accessible, and more user-friendly systems for individuals with diabetes”
This event has been organized in collaboration with the Diabetes Technology Society, the Helmsley Charitable Trust, the JDRF, and the U.S. Food and Drug Administration.
Organizing Committee
Guillermo Arreaza-Rubín, M.D.
Director, Diabetes Technology Program
Division of Diabetes, Endocrinology, and Metabolic Diseases
National Institute of Diabetes and Digestive and Kidney Diseases
National Institutes of Health
Andrew Bremer, M.D., Ph.D.
Chief, Pediatric Growth and Nutrition Branch
Division of Extramural Research
National Institute of Child Health and Human Development
National Institutes of Health
Miranda Broadney, M.D.
Director, Type 1 Diabetes Therapeutics program.
Division of Diabetes, Endocrinology, and Metabolic Diseases
National Institute of Diabetes and Digestive and Kidney Diseases
National Institutes of Health
Deniz Dalton, M.S.
Program Officer for the T1D Program
The Leona M. and Harry B. Helmsley Charitable Trust
Thomas Eggerman, M.D., Ph.D.
Program Director for Artificial Pancreas Clinical Trials
Division of Diabetes, Endocrinology, and Metabolic Diseases
National Institute of Diabetes and Digestive and Kidney Diseases
National Institutes of Health
Jessica Flynn, Ph.D.
Division of Chemistry and Toxicology, Diabetes Diagnostic Devices Branch
Center for Devices and Radiological Health
U.S. Food and Drug Administration
Jaime Giraldo, Ph.D.
Associate Director of Research
JDRF
David C. Klonoff, M.D.
President, Diabetes Technology Society
Medical Director, Diabetes Research Institute
Mills-Peninsula Health Services
Marjana Marinac, Pharm.D.
Senior Director, Regulatory Affairs
JDRF
Jonathan Rosen, Ph.D.
Director of Research
JDRF
Sean Sullivan, Ph.D.
Senior Program Officer, Type 1 Diabetes
The Leona M. and Harry B. Helmsley Charitable Trust
Registration Deadline
April 27, 2023
Event Logistics
Registration
Location
National Institutes of Health
Bethesda,
MD
20894
Webinar
This is a hybrid workshop. Virtual participation is available. For those attending via webinar, the link will be distributed via email prior to the date of the event.
Contacts
Program Contact
Guillermo Arreaza-Rubin, M.D.
NIDDK
T: 301-594-4724
Meeting Logistics
Mark Dennis
The Scientific Consulting Group, Inc.
T: 301-670-4990